Makary Doubles Down on Push to ‘Modernize’ FDA, Eyes Speedier Reviews

Speaking at BIO 2025, Makary bemoaned what he called “unnecessary steps” and “avoidable delays” in the U.S. regulatory landscape.

Scroll to Top